Cargando…

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma

The “macrotrabecular-massive” (MTM) pattern of hepatocellular carcinoma (HCC) has been suggested to represent a distinct HCC subtype and is associated with specific molecular features. Since the immune microenvironment is heterogenous in HCC, it is important to evaluate the immune microenvironment o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Li-Li, Zhang, Shi-Wen, Chao, Xue, Wang, Chun-Hua, Yang, Xia, Zhang, Xin-Ke, Wen, Yan-lin, Yun, Jing-Ping, Luo, Rong-Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889680/ https://www.ncbi.nlm.nih.gov/pubmed/32770259 http://dx.doi.org/10.1007/s00262-020-02691-9

Ejemplares similares

Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know?
por: Li, Xiaoming, et al.
Publicado: (2022)

Corona enhancement combined with microvascular invasion for prognosis prediction of macrotrabecular-massive hepatocellular carcinoma subtype
por: Yang, Lili, et al.
Publicado: (2023)

Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge
por: Sessa, Anna, et al.
Publicado: (2022)

Nomogram for the Preoperative Prediction of the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma
por: Shan, Yuying, et al.
Publicado: (2022)

Recognising the clinically significant macrotrabecular massive variant of hepatocellular carcinoma
por: Seow, Dominique Yuan Bin, et al.
Publicado: (2022)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Comparison of computed tomography and magnetic resonance imaging findings and histopathological features of macrotrabecular-massive hepatocellular carcinoma
por: Gong, Qishu, et al.
Publicado: (2023)

Macrotrabecular-massive subtype-based nomogram to predict early recurrence of hepatocellular carcinoma after surgery
por: Yang, Yong, et al.
Publicado: (2023)

Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma
por: Dai, Xiaomeng, et al.
Publicado: (2018)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma through dynamic contrast-enhanced magnetic resonance imaging-based radiomics
por: Zhang, Yang, et al.
Publicado: (2023)

Tumor metabolism derived from (18)F-FDG PET/CT in predicting the macrotrabecular-massive subtype of hepatocellular carcinoma
por: Hu, Siqi, et al.
Publicado: (2022)

Preoperative prediction model for macrotrabecular-massive hepatocellular carcinoma based on contrast-enhanced CT and clinical characteristics: a retrospective study
por: He, Chutong, et al.
Publicado: (2023)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

Clinical significance of CMTM4 expression in hepatocellular carcinoma
por: Bei, Chunhua, et al.
Publicado: (2017)

Development and validation of MRI-based model for the preoperative prediction of macrotrabecular hepatocellular carcinoma subtype
por: Bilal Masokano, Ismail, et al.
Publicado: (2022)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
por: Li, Xin, et al.
Publicado: (2020)

CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas
por: Guan, Xiudong, et al.
Publicado: (2018)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
por: Song, Xin, et al.
Publicado: (2021)

Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma
por: Tan, Shengkui, et al.
Publicado: (2022)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

Coexpression of EGFR and CXCR4 Predicts Poor Prognosis in Resected Pancreatic Ductal Adenocarcinoma
por: Wu, Huanwen, et al.
Publicado: (2015)

CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer
por: Wu, Xuehui, et al.
Publicado: (2021)

CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer
por: Si, Jiahui, et al.
Publicado: (2017)

Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma
por: Pei, Yulin, et al.
Publicado: (2023)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer
por: Tian, Yiping, et al.
Publicado: (2021)

Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‐L1
por: Chui, Noreen Nog‐Qin, et al.
Publicado: (2021)

CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma
por: Yugawa, Kyohei, et al.
Publicado: (2020)

Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
por: Zhang, Shidong, et al.
Publicado: (2020)

CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis
por: Jia, Daqi, et al.
Publicado: (2023)

CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer
por: Zhou, Zixuan, et al.
Publicado: (2021)

Expression of CMTM4 shows clinical significance in lung cancer
por: Zhu, Xiaonian, et al.
Publicado: (2020)

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer
por: Yin, Bo, et al.
Publicado: (2022)

CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer
por: Su, Yu, et al.
Publicado: (2014)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
por: Gao, Feng, et al.
Publicado: (2019)

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review
por: Li, Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mgglbsonj9itgcfah6f24d1ls8